Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA sequencing of CRC tumor organoids engineered with key driver mutations

ABSTRACT: We profiled CRC organoids engineered with different combinations of driver mutations. All organoids were derived from one mouse and then mutations were sequentially introduced by CRISPR Cas9

ORGANISM(S): Mus musculus

PROVIDER: GSE207668 | GEO | 2022/09/16

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

RNA sequencing of CRC tumor organoids engineered with key driver mutations

Project description:RNA sequencing of CRC tumor organoids engineered with key driver mutations

| PRJNA856659 | ENA

An engineered pancreatic cancer model with intra-tumoral heterogeneity of driver mutations.

Project description:Pancreatic ductal adenocarcinoma (PDAC) is a complex disease with significant intra-tumoral heterogeneity (ITH). Currently, no reliable PDAC tumor model is available that can present ITH profiles in a controlled manner. We develop an in vitro microfluidic tumor model mimicking the heterogeneous accumulation of key driver mutations of human PDAC using cancer cells derived from genetically engineered mouse models. These murine pancreatic cancer cell lines have KPC (Kras and Trp53 mutations) and KIC genotypes (Kras mutation and Cdkn2a deletion). Also, the KIC genotypes have two distinct phenotypes - mesenchymal or epithelial. The tumor model mimics the ITH of human PDAC to study the effects of ITH on the gemcitabine response. The results show gemcitabine resistance induced by ITH. Remarkably, it shows that cancer cell-cell interactions induce the gemcitabine resistance potentially through epithelial-mesenchymal-transition. The tumor model can provide a useful testbed to study interaction mechanisms between heterogeneous cancer cell subpopulations.

| S-EPMC9178523 | biostudies-literature

Inactivation of Bap1 Cooperates with Losses of Nf2 and Cdkn2a to Drive the Development of Pleural Malignant Mesothelioma in Conditional Mouse Models

Project description:Mutations/deletions of BAP1, CDKN2A, and NF2 are the most frequent genetic lesions in human MM. We introduced various combinations of these deletions in the pleura of conditional knockout (CKO) mice, focusing on the contribution of Bap1 loss.

2019-05-30 | GSE131942 | GEO

ATAC-sequencing of genetically engineered intestinal organoid lines modeling colorectal cancer (CRC) progression

Project description:To characterize changes in chromatin accessibility acorss the CRC malignancy continum, wild type organoids (WT), ApcKO (A) and ApcKO::KrasG12D::Smad4KO::Trp53KO (AKSP) tumoroids were subjected to bulk ATAC-seq. We then performed differential accessibility analysis using data obtained from ATAC-seq of the indicated organoid lines.

2024-10-17 | GSE239752 | GEO

RNA-sequencing of genetically engineered intestinal organoid lines modeling colorectal cancer (CRC) progression

Project description:To characterize the transcriptional changes acorss the CRC malignancy continum, wild type organoids (WT), ApcKO (A) and ApcKO::KrasG12D::Smad4KO::Trp53KO (AKSP) tumoroids were subjected to bulk RNA_seq. We then performed gene expression profiling analysis using data obtained from mRNA-seq of the indicated organoid lines.

2024-10-17 | GSE239754 | GEO

Transcriptomic characterization of FLC-mutant engineered human hepatocyte organoids

Project description:We engineered human hepatocyte organoids to study the effect of different fibrolamellar carcinoma mutations. To study the effects and differences between the different mutations, we performed bulk RNA-sequencing to understand the transcriptomic changes.

2023-03-15 | GSE215785 | GEO

Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer.

Project description:Small-cell lung cancer (SCLC) is an aggressive lung tumor subtype with poor prognosis. We sequenced 29 SCLC exomes, 2 genomes and 15 transcriptomes and found an extremely high mutation rate of 7.4±1 protein-changing mutations per million base pairs. Therefore, we conducted integrated analyses of the various data sets to identify pathogenetically relevant mutated genes. In all cases, we found evidence for inactivation of TP53 and RB1 and identified recurrent mutations in the CREBBP, EP300 and MLL genes that encode histone modifiers. Furthermore, we observed mutations in PTEN, SLIT2 and EPHA7, as well as focal amplifications of the FGFR1 tyrosine kinase gene. Finally, we detected many of the alterations found in humans in SCLC tumors from Tp53 and Rb1 double knockout mice. Our study implicates histone modification as a major feature of SCLC, reveals potentially therapeutically tractable genomic alterations and provides a generalizable framework for the identification of biologically relevant genes in the context of high mutational background.

| S-EPMC4915822 | biostudies-literature

Targeted DNA sequencing of uveal melanoma driver mutations

Project description:Targeted DNA sequencing of uveal melanoma driver mutations

| PRJNA1258313 | ENA

Targeted DNA sequencing of uveal melanoma driver mutations

Project description:Targeted DNA sequencing of uveal melanoma driver mutations

| PRJNA1258314 | ENA

Organoids derived from mouse normal colon and tumor samples with Apc, Kras, and Trp53 mutations in several combinations.

Project description:Organoids derived from mouse normal colon and tumor samples with Apc, Kras, and Trp53 mutations in several combinations.

| PRJNA515710 | ENA